Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -5.85%18 Equity-to-Asset is 0.75 as of Mar. 2026, which is 47% above its 10-year median of 0.51. GuruFocus rates HKPD with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 123 Medical Distribution companies, Cellyan Biotechnology Co ranks better than 90.24% on this metric.
Cellyan Biotechnology Co (NAS:HKPD) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cellyan Biotechnology Co Equity-to-Asset Related Terms
Cellyan Biotechnology Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKPD vs COSM, YI, MEDS: Equity-to-Asset Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Equity-to-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Equity-to-Asset falls into.
Cellyan Biotechnology Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cellyan Biotechnology Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a Equity-to-Asset of 0.75 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cellyan Biotechnology Co and its competitors. This is 47% above median its historical median of 0.51. Over the past decade, Cellyan Biotechnology Co's Equity-to-Asset has ranged from 0.17 to 0.75. According to the industry distribution chart, Cellyan Biotechnology Co ranks #12 out of 123 companies in the Medical Distribution industry, placing it in the top 9.8%.
Is Cellyan Biotechnology Co's Equity-to-Asset too high?
Cellyan Biotechnology Co's current Equity-to-Asset of 0.75 is 47% above median its 10-year median of 0.51. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 0.75. The Medical Distribution industry median Equity-to-Asset is 0.40. Cellyan Biotechnology Co's value of 0.75 is 87.5% above this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #12 out of 123 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Equity-to-Asset compare to COSM and YI?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #12 out of 123 companies for Equity-to-Asset. This places Cellyan Biotechnology Co in the top 10% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.40. Cellyan Biotechnology Co's value of 0.75 is 87.5% above this benchmark. Historically, Cellyan Biotechnology Co's own Equity-to-Asset has ranged from 0.17 to 0.75 over the past decade. While the company's 10-year median is 0.51 vs. the industry median of 0.40, Cellyan Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Distribution company?
The median Equity-to-Asset among Medical Distribution companies is 0.40, based on 123 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Equity-to-Asset of 0.75 is 87.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Equity-to-Asset is 0.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Equity-to-Asset is 0.75, which is 47% above median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Equity-to-Asset of 0.75. The current Equity-to-Asset is 0.75, which is 47% above median its 10-year median of 0.51 and 87.5% above the Medical Distribution industry median of 0.40. Cellyan Biotechnology Co's overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Equity-to-Asset is 0.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
18GF Score
Get the complete analysis for HKPD
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
